As preclinical studies and clinical trials advance, the use of CDK4/6 inhibitors—particularly in combination regimens—is anticipated to become increasingly widespread, potentially extending therapeutic benefits to a growing number of cancer patients. This evidence concerns the gene CDK4 and cancer.